ARS Pharmaceuticals, Inc (SPRY) — Capital Reinvestment Ratio
Latest as of December 2024:
0.01x
ARS Pharmaceuticals, Inc (SPRY) has a Capital Reinvestment Ratio of 0.01x as of December 2024, meaning it reinvests 0% of its operating cash flow ($42.00 Million) in capital expenditures ($302.00K). See SPRY free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.01x
Capex / Operating Cash Flow
Operating Cash Flow
$42.00 Million
USD
Capital Expenditures
$302.00K
USD
Data as of
Dec 2024
Most recent filing
ARS Pharmaceuticals, Inc Capital Reinvestment Ratio (2020–2024)
This chart tracks ARS Pharmaceuticals, Inc's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for ARS Pharmaceuticals, Inc (2020–2024)
Year-by-year Capital Reinvestment Ratio for ARS Pharmaceuticals, Inc from 2020 to 2024. For live market cap and broader valuation context, see SPRY market cap overview.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.04x | $13.55 Million | $563.00K | ▼ -58.9% |
| 2020 | 0.10x | $9.07 Million | $917.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow